Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | FRK | P42685 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9258940 | 0.85 | MKNK1 (0.57) | NTRK1MKNK1MAPK1MAP2K4ALDH1A1 | |
| SCHEMBL1921806 | 0.83 | MKNK1 (0.47) | MAPK14MKNK1MAPK1MAP2K4ALDH1A1 | |
| SCHEMBL1922328 | 0.83 | MAP2K4 (0.56) | MKNK1ACHEMAPK1MAP2K4ALDH1A1 | |
| SCHEMBL9251358 | 0.83 | CLK2 (0.54) | MAPK14MKNK1MAPK1MAP2K4ALDH1A1 | |
| SCHEMBL1513103 | 0.82 | IDO1 (0.63) | MKNK1ACHEMAP2K4ALDH1A1LRRK2 | |
| Hydrochloric Acid SCHEMBL9260992 | 0.81 | MKNK1 (0.46) | MAPK14MKNK1MAPK1MAP2K4ALDH1A1 | |
| SCHEMBL4153296 | 0.81 | CLK2 (0.52) | MAPK14NTRK1MKNK1ACHEMAP2K4 | |
| SCHEMBL2242478 | 0.79 | LRRK2 (0.59) | MAPK14MKNK1LRRK2IDO1MAPK13 | |
| SCHEMBL5377572 | 0.77 | ALDH1A1 (0.71) | MAPK1MAP2K4ALDH1A1LRRK2SMN1; SMN2 | |
| SCHEMBL27817994 | 0.76 | MAPT (0.59) | MAPK14MKNK1MAPK1ALDH1A1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107150-A1 | New Compounds II | PROXIMAGEN LTD (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107150-A1 | New Compounds II | PROXIMAGEN LTD (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107150-A1 | New Compounds II | PROXIMAGEN LTD (GB) | 2014-04-17 | — | — | US | disclosed |
| US-8633318-B2 | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder | PROXIMAGEN LTD (GB) | 2014-01-21 | — | — | US | disclosed |
| US-8633318-B2 | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder | PROXIMAGEN LTD (GB) | 2014-01-21 | — | — | US | disclosed |
| US-8633318-B2 | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder | PROXIMAGEN LTD (GB) | 2014-01-21 | — | — | US | disclosed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2328895-A1 | NEW COMPOUNDS II | Proximagen Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010031791-A1 | NEW COMPOUNDS II | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010031791-A1 | NEW COMPOUNDS II | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195992-A1 | NEW COMPOUNDS II | SSB, NFKBIA, ALOX15B | MAPK14 3464/4885NTRK1 4569/4885MKNK1 4110/4885 |
| US-20140107150-A1 | New Compounds II | SSB, NFKBIA, ALOX15B | MAPK14 3464/4885NTRK1 4569/4885MKNK1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.